Literature DB >> 7334463

Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

L B Sheiner, S L Beal.   

Abstract

Individual pharmacokinetic parameters quantify the pharmacokinetics of an individual, while population pharmacokinetic parameters quantify population mean-kinetics, interindividual variability, and residual variability, including intraindividual variability and measurement error. Individual pharmacokinetics are estimated by fitting individual data to a pharmacokinetic model. Population pharmacokinetic parameters have been estimated either by fitting all individuals' data together as though there were no individual kinetic difference, the naive pooled data (NPD) approach, or by fitting each individuals' data separately and then combining the individual parameter estimates, the two stage (TS) approach. A third approach, NONMEM, takes a middle course between these. This study provides further evidence of NONMEM's validity by comparing, using simulation, the three approaches on three types of data sets corresponding to three typical types of pharmacokinetic studies. The estimates of population parameters provided by the NPD method are poorer than those provided by either of the other methods. The estimates provided by the TS method are adequate for mean values and for residual variability, but not for interindividual kinetic variability. NONMEM's estimates are as good as those of the TS method for mean parameters and for residual variability, and considerably better for interindividual variability. The latter estimates are still not acceptable in an absolute sense. This is probably due, not to an intrinsic fault of the method (as it is in the case of the TS approach), but to an insufficient number of individuals being studied.

Mesh:

Substances:

Year:  1981        PMID: 7334463     DOI: 10.1007/bf01061030

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  2 in total

1.  The pharmacokinetics of d-tubocurarine in man with and without renal failure.

Authors:  R D Miller; R S Matteo; L Z Benet; Y J Sohn
Journal:  J Pharmacol Exp Ther       Date:  1977-07       Impact factor: 4.030

2.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
  2 in total
  85 in total

1.  Predictive performance of a semiparametric method to estimate population pharmacokinetic parameters using NONMEM.

Authors:  F Bressolle; R Gomeni
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

2.  Nonlinearity detection: advantages of nonlinear mixed-effects modeling.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  AAPS PharmSci       Date:  2000

3.  Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

4.  A computationally efficient approach for the design of population pharmacokinetic studies.

Authors:  J Wang; L Endrenyi
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

5.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

6.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

Review 7.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

8.  Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers.

Authors:  Carol Cronenberger; Diane R Mould; Hans-Juergen Roethig; Mohamadi Sarkar
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

9.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.